2024 Q2 Form 10-Q Financial Statement

#000162828024020862 Filed on May 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $73.83M $137.7M $24.33M
YoY Change 186.33% 466.14% 29.16%
Cost Of Revenue $15.61M $10.08M $11.65M
YoY Change 130.02% -13.53% 63.54%
Gross Profit $58.23M $127.7M $12.68M
YoY Change 206.45% 907.02% 8.25%
Gross Profit Margin 78.86% 92.69% 52.11%
Selling, General & Admin $44.19M $41.99M $29.90M
YoY Change 30.11% 40.42% -1.58%
% of Gross Profit 75.89% 32.89% 235.87%
Research & Development $11.46M $13.40M $31.38M
YoY Change -48.14% -57.29% 29.04%
% of Gross Profit 19.68% 10.5% 247.54%
Depreciation & Amortization $10.00K $0.00 $81.00K
YoY Change -80.39% -100.0% -47.06%
% of Gross Profit 0.02% 0.0% 0.64%
Operating Expenses $71.26M $65.47M $72.93M
YoY Change 27.11% -10.24% 17.97%
Operating Profit $2.579M $72.27M -$48.61M
YoY Change -106.96% -248.69% 13.06%
Interest Expense -$11.32M $14.02M $14.39M
YoY Change -21.57% -2.52% 2.31%
% of Operating Profit -439.05% 19.41%
Other Income/Expense, Net $2.454M $2.777M $1.273M
YoY Change 57.31% 118.15% 297.81%
Pretax Income -$61.93M $61.02M -$61.72M
YoY Change 24.01% -198.87% 8.79%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$61.93M $61.02M -$61.72M
YoY Change 24.01% -198.87% 8.79%
Net Earnings / Revenue -83.87% 44.3% -253.68%
Basic Earnings Per Share -$0.33 $0.36 -$0.79
Diluted Earnings Per Share -$0.33 $0.34 -$0.79
COMMON SHARES
Basic Shares Outstanding 189.5M shares 185.1M shares 76.57M shares
Diluted Shares Outstanding 188.8M shares 189.6M shares 78.44M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $189.3M $226.6M $162.3M
YoY Change 36.71% 39.59% -25.7%
Cash & Equivalents $189.3M $226.6M $144.9M
Short-Term Investments $17.43M
Other Short-Term Assets $10.98M $11.29M $12.50M
YoY Change 52.86% -9.68% 8.25%
Inventory $84.47M $73.10M $39.35M
Prepaid Expenses
Receivables $60.36M $54.61M $36.42M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $345.1M $365.6M $250.6M
YoY Change 48.67% 45.89% -13.83%
LONG-TERM ASSETS
Property, Plant & Equipment $307.0K $268.0K $83.00K
YoY Change -87.44% 222.89% -83.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $7.211M $7.454M $1.214M
YoY Change 188.32% 514.0% -97.67%
TOTAL ASSETS
Total Short-Term Assets $345.1M $365.6M $250.6M
Total Long-Term Assets $7.211M $7.454M $1.214M
Total Assets $352.3M $373.1M $251.8M
YoY Change 50.16% 48.15% -26.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.67M $28.43M $17.07M
YoY Change 94.11% 66.62% -36.39%
Accrued Expenses $74.24M $63.24M $39.34M
YoY Change 67.98% 60.75% 12.19%
Deferred Revenue $20.67M $29.35M $12.16M
YoY Change 32.22% 141.42% 220.34%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $175.3M $164.5M $95.49M
YoY Change 63.6% 72.29% 20.74%
LONG-TERM LIABILITIES
Long-Term Debt $262.5M $262.0M $260.3M
YoY Change 0.67% 0.66% 0.63%
Other Long-Term Liabilities $258.7M $240.8M $225.7M
YoY Change 8.39% 6.71% -11.2%
Total Long-Term Liabilities $521.2M $502.8M $486.0M
YoY Change 4.36% 3.47% -5.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $175.3M $164.5M $95.49M
Total Long-Term Liabilities $521.2M $502.8M $486.0M
Total Liabilities $696.5M $667.4M $581.5M
YoY Change 14.83% 14.77% -1.76%
SHAREHOLDERS EQUITY
Retained Earnings -$1.550B -$1.488B -$1.402B
YoY Change 6.78% 6.17% 20.52%
Common Stock $195.0K $188.0K $87.00K
YoY Change 93.07% 116.09% 42.62%
Preferred Stock
YoY Change
Treasury Stock (at cost) $55.00M
YoY Change 0.0%
Treasury Stock Shares 1.994M shares
Shareholders Equity -$344.2M -$294.3M -$329.7M
YoY Change
Total Liabilities & Shareholders Equity $352.3M $373.1M $251.8M
YoY Change 50.16% 48.15% -26.55%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$61.93M $61.02M -$61.72M
YoY Change 24.01% -198.87% 8.79%
Depreciation, Depletion And Amortization $10.00K $0.00 $81.00K
YoY Change -80.39% -100.0% -47.06%
Cash From Operating Activities -$7.205M $53.83M -$54.36M
YoY Change -70.89% -199.03% 39.41%
INVESTING ACTIVITIES
Capital Expenditures $77.00K $73.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $25.00M
YoY Change -100.0% -100.0% -238.11%
Cash From Investing Activities -$77.00K -$73.00K $25.00M
YoY Change -100.44% -100.29% -238.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -30.02M $90.61M $49.49M
YoY Change -3811.12% 83.07% -3546.52%
NET CHANGE
Cash From Operating Activities -7.205M $53.83M -$54.36M
Cash From Investing Activities -77.00K -$73.00K $25.00M
Cash From Financing Activities -30.02M $90.61M $49.49M
Net Change In Cash -37.31M $144.4M $20.14M
YoY Change 479.18% 616.93% -134.4%
FREE CASH FLOW
Cash From Operating Activities -$7.205M $53.83M -$54.36M
Capital Expenditures $77.00K $73.00K $0.00
Free Cash Flow -$7.282M $53.76M -$54.36M
YoY Change -198.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
29350000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
25402000 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2539000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1553000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
164512000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
156224000 usd
CY2024Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
262033000 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
261596000 usd
CY2024Q1 espr Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
236397000 usd
CY2023Q4 espr Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
239950000 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4416000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3020000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
667358000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
660790000 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
480000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
480000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
189849296 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
120204513 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
188000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
118000 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1248774000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1149170000 usd
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1994198 shares
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1994198 shares
CY2024Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
54998000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
54998000 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1488262000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1549284000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-294298000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-454994000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
373060000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
205796000 usd
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
137735000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24329000 usd
CY2024Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
10075000 usd
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
11652000 usd
CY2024Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
13403000 usd
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
31381000 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
41988000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29901000 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
65466000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
72934000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
72269000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-48605000 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
14024000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
14387000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2777000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1273000 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
61022000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-61719000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
169258564 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78440266 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189641251 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78440266 shares
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
61022000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61718000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-323778000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
502000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2903000 usd
CY2023Q1 espr Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
52428000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-61719000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-329663000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-454994000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3235000 usd
CY2024Q1 espr Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
90672000 usd
CY2024Q1 espr Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
5766000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
61022000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-294298000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
61022000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-61719000 usd
CY2024Q1 us-gaap Depreciation
Depreciation
0 usd
CY2023Q1 us-gaap Depreciation
Depreciation
81000 usd
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 usd
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
339000 usd
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
437000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
417000 usd
CY2024Q1 espr Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
10937000 usd
CY2023Q1 espr Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
11320000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3235000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2903000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6118000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2686000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6590000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1608000 usd
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3948000 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
8650000 usd
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7472000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4151000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3450000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5975000 usd
CY2024Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2121000 usd
CY2023Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1249000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
53828000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54356000 usd
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
0 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
25000000 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25000000 usd
CY2024Q1 espr Payments From Revenue Interest Purchase Agreement
PaymentsFromRevenueInterestPurchaseAgreement
5832000 usd
CY2023Q1 espr Payments From Revenue Interest Purchase Agreement
PaymentsFromRevenueInterestPurchaseAgreement
3106000 usd
CY2024Q1 espr Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockWarrantsAndPreFundedWarrantsNetOfIssuanceCosts
0 usd
CY2023Q1 espr Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockWarrantsAndPreFundedWarrantsNetOfIssuanceCosts
52598000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
90672000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5766000 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
90606000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2005000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49492000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
144361000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20136000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82248000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124775000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
226609000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144911000 usd
CY2024Q1 espr Common Stock Issuance Costs Incurred Not Yet Paid
CommonStockIssuanceCostsIncurredNotYetPaid
0 usd
CY2023Q1 espr Common Stock Issuance Costs Incurred Not Yet Paid
CommonStockIssuanceCostsIncurredNotYetPaid
170000 usd
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
195000 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
CY2024Q1 espr Non Cash Right Of Use Asset
NonCashRightOfUseAsset
72000 usd
CY2023Q1 espr Non Cash Right Of Use Asset
NonCashRightOfUseAsset
1000 usd
CY2020 espr Number Of Products Approved
NumberOfProductsApproved
2 product
CY2019Q3 espr Estimated Number Of Study Patients
EstimatedNumberOfStudyPatients
14000 patient
CY2024Q1 espr Settlement Agreement Aggregate First Milestone Payment From Partner
SettlementAgreementAggregateFirstMilestonePaymentFromPartner
100000000 usd
CY2024Q1 espr Settlement Agreement Time Required To Pay Cash Portion Of Settlement
SettlementAgreementTimeRequiredToPayCashPortionOfSettlement
P15D
CY2024Q1 espr Settlement Agreement Aggregate Second Milestone Payment From Partner
SettlementAgreementAggregateSecondMilestonePaymentFromPartner
25000000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
CY2024Q1 us-gaap Inventory Net
InventoryNet
73095000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
65623000 usd
CY2023Q2 espr Potential Proceeds From Partner Milestone Payments
PotentialProceedsFromPartnerMilestonePayments
300000000 usd
CY2024Q1 espr Settlement Agreement Aggregate First Milestone Payment From Partner
SettlementAgreementAggregateFirstMilestonePaymentFromPartner
100000000 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of March 31, 2024 and December 31, 2023, eleven customers accounted for all of the Company's net trade receivables. As of March 31, 2024 and December 31, 2023, three customers hold approximately 99% and 96% of the Company's trade receivables associated with net product sales, respectively. In the three months ended March 31, 2024 and 2023, three customers accounted for approximately 99% and 99% of gross sales of NEXLETOL and NEXLIZET, respectively.</span></div>
CY2024Q1 espr Number Of Sources Of Revenue
NumberOfSourcesOfRevenue
2 revenue_source
CY2024Q1 espr Settlement Agreement Aggregate First Milestone Payment From Partner
SettlementAgreementAggregateFirstMilestonePaymentFromPartner
100000000 usd
CY2024Q1 espr Settlement Agreement Time Required To Pay Cash Portion Of Settlement
SettlementAgreementTimeRequiredToPayCashPortionOfSettlement
P15D
CY2024Q1 espr Settlement Agreement Aggregate Second Milestone Payment From Partner
SettlementAgreementAggregateSecondMilestonePaymentFromPartner
25000000 usd
CY2024Q1 espr Settlement Agreement Aggregate First Milestone Payment From Partner
SettlementAgreementAggregateFirstMilestonePaymentFromPartner
100000000 usd
CY2024Q1 espr Settlement Agreement Aggregate Second Milestone Payment From Partner
SettlementAgreementAggregateSecondMilestonePaymentFromPartner
25000000 usd
CY2024Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
67116000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
61890000 usd
CY2024Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3563000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1728000 usd
CY2024Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2416000 usd
CY2024Q1 espr Settlement Agreement Time Required To Pay Cash Portion Of Settlement
SettlementAgreementTimeRequiredToPayCashPortionOfSettlement
P15D
CY2024Q1 espr Settlement Agreement Aggregate Second Milestone Payment From Partner
SettlementAgreementAggregateSecondMilestonePaymentFromPartner
25000000 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
195490000 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
195490000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
68847000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
68847000 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q1 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
0 usd
CY2023Q1 espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0 usd
CY2024Q1 espr Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
0 usd
CY2022Q4 espr One Time Partial Call
OneTimePartialCall
50000000 usd
CY2024Q1 espr Revenue Interest Payments Redemption Percentage
RevenueInterestPaymentsRedemptionPercentage
2.25
CY2024Q1 espr Revenue Interest Payments Redemption Value
RevenueInterestPaymentsRedemptionValue
400000000 usd
CY2024Q1 espr Revenue Interest Payments Remaining Redemption Value
RevenueInterestPaymentsRemainingRedemptionValue
366700000 usd
CY2020Q4 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
46000000 usd
CY2020Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
55000000 usd
CY2020Q4 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
46000000 usd
CY2020Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
55000000 usd
CY2020Q4 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
1994198 shares
CY2024Q1 us-gaap Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
448698 shares
CY2024Q1 espr Accrued Legal Fees Current
AccruedLegalFeesCurrent
9662000 usd
CY2023Q4 espr Accrued Legal Fees Current
AccruedLegalFeesCurrent
9202000 usd
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5966000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10769000 usd
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3247000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2712000 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3975000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1325000 usd
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
290000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
990000 usd
CY2024Q1 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
23140000 usd
CY2023Q4 espr Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
24998000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3686191 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.88
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M19D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
584000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1757000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.05
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
47000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
24.57
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5396191 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.94
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M4D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1569000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5396191 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.94
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M4D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1569000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1847040 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
22.25
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
30000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2900000 usd
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32344212 shares
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
36344212 shares
CY2024Q1 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2650000 usd
CY2023Q1 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
63672000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-61719000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
169258564 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78440266 shares
CY2024Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
11713131 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2024Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
8007010 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2024Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
20382687 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189641251 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78440266 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7866758 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
86292792 shares

Files In Submission

Name View Source Status
espr-20240331_cal.xml Edgar Link unprocessable
espr-20240331_def.xml Edgar Link unprocessable
0001628280-24-020862-index-headers.html Edgar Link pending
0001628280-24-020862-index.html Edgar Link pending
0001628280-24-020862.txt Edgar Link pending
0001628280-24-020862-xbrl.zip Edgar Link pending
a1023rdamendmentdse.htm Edgar Link pending
a103ds1stamendment.htm Edgar Link pending
espr-20240331.htm Edgar Link pending
espr-20240331.xsd Edgar Link pending
espr-ex311x03312024.htm Edgar Link pending
espr-ex312x03312024.htm Edgar Link pending
espr-ex321x03312024.htm Edgar Link pending
exhibit101settlementagreem.htm Edgar Link pending
espr-20240331_lab.xml Edgar Link unprocessable
espr-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
espr-20240331_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending